Skip to content

8-KAccepted Aug 3, 4:02 PM ET

Keros Therapeutics Reports Results for Quarter Ended June 30, 2026

KROSKeros Therapeutics, Inc.

Accepted (ET)

4:02 PM

Aug 3, 2026

Filed

Aug 3, 2026

Documents

12

Size

256.9 KB

Summary

Keros Therapeutics Reports Results for Quarter Ended June 30, 2026

Updated

What Happened
Keros Therapeutics, Inc. filed a Form 8-K on August 3, 2026 (Item 2.02) to announce its financial results for the quarter ended June 30, 2026. The company issued a press release dated August 3, 2026, which was furnished as Exhibit 99.1 to the filing.

Key Details

  • Filing date: August 3, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
  • Period covered: quarter ended June 30, 2026.
  • Press release: furnished as Exhibit 99.1 (dated August 3, 2026).
  • Inline XBRL cover page included (Exhibit 104) for interactive data.

Why It Matters
This 8-K provides Keros’s most recent quarterly earnings and financial condition information that investors and analysts use to evaluate the company’s performance (e.g., revenue, expenses, cash position and operational updates). Review the furnished press release (Exhibit 99.1) for the specific figures and narrative behind the results to inform investment decisions or follow-up questions.

AI-written summary · check the filing